Scientists from Jiangsu Hengrui Pharmaceuticals Co. Ltd., Shanghai Senhui Pharmaceutical Co. Ltd. and Shanghai Shengdi Pharmaceutical Co. Ltd. have disclosed antibody-drug conjugates comprising antibodies covalently linked camptothecin derivatives through a linker reported to be useful for the treatment of cancer.
Homozygous deletion of methylthioadenosine phosphorylase (MTAP), present in ~15% of tumors, leads to accumulation of methylthioadenosine and partial inhibition of protein arginine methyltransferase 5 (PRMT5), creating a synthetic-lethal vulnerability that sensitizes tumors to PRMT5-targeted therapies. Researchers from Beone Medicines Ltd. presented preclinical efficacy data of BGB-58067, an MTA-cooperative PRMT5 inhibitor, in models of tumors with MTAP-deficiency.
An advantage of antibody-drug conjugates (ADCs) is that they allow targeted delivery of cytotoxic agents into tumors, thus improving the therapeutic index. Pfizer Inc. has developed a new ADC, PF-08046033, that contains auristatin S (AurS) as the cytotoxic payload and targets transmembrane glycoprotein NMB (GPNMB).
Neomorph Inc.’s NEO-811 is a molecular glue degrader designed to induce targeted degradation of ARNT and suppress this signaling pathway implicated in clear cell renal cell carcinoma (ccRCC). Targeting ARNT offers a complementary strategy to broadly disrupt oncogenic HIF signaling in ccRCC.
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision. As increasingly sensitive technologies reveal traces of cancer that persist after therapy, MRD is emerging as both a biological challenge and a clinical opportunity, especially as new data illuminate its complexity across hematologic and solid tumors. This topic was addressed at the 2026 American Association for Cancer Research (AACR) annual meeting.
Shanghai Fosun Pharmaceutical Industry Development Co. Ltd. has patented Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
Mabwell (Shanghai) Bioscience Co. Ltd. has synthesized antibody-drug conjugates comprising antibody or antigen-binding fragment targeting disintegrin and metalloproteinase domain-containing protein 9 (ADAM9) covalently linked to a cytotoxic drug. They are described as potentially useful for the diagnosis and/or treatment of cancer.
Avacta Life Sciences Ltd. has disclosed drug conjugates consisting of a fibroblast activation protein-α (FAPα) cleavable moiety bonded to camptothecin derivatives through a linker that are potentially useful for the treatment of cancer, inflammation and fibrosis.
The major histocompatibility complex class I polypeptide-related sequences A and B (MICA/B) are frequently expressed by cancer cells. In a recently published study, researchers from Icahn School of Medicine at Mount Sinai hypothesized that the therapeutic efficacy of anti-MICA/B antibodies could be enhanced through Fc optimization with three point mutations in the Fc region: G236A, A330L and I332E (GAALIE).
RSS
